AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34463842 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed ranibizumab and TRP
Number of subjects: 40
Study 34463842 — intervention group
Group type: COMPARATOR
Intervention: All cohorts
Number of subjects: 40
Study 34088700 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability to T2D
Number of subjects: 0
Study 34088700 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically instrumented higher insulin resistance (IR)
Number of subjects: 0
Study 34088700 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability to HF
Number of subjects: 0
Study 34088700 — intervention group
Group type: COMPARATOR
Intervention: Fasting insulin, glucose, or glycated hemoglobin
Number of subjects: 0
Study 32297772 — intervention group
Group type: EXPERIMENTAL
Intervention: Type D personality
Number of subjects: 70
Study 32297772 — intervention group
Group type: COMPARATOR
Intervention: Non-Type D personality
Number of subjects: 70
Study 35680613 — intervention group
Group type: EXPERIMENTAL
Intervention: GI Genius™-assisted colonoscopy
Number of subjects: 1828
Study 35680613 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 1828
Study 32125906 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 0
Study 35008045 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth with no home visits
Number of subjects: 2626
Study 35008045 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth with two home visits
Number of subjects: 2626
Study 35008045 — intervention group
Group type: COMPARATOR
Intervention: Standard message arm
Number of subjects: 2626
Study 32204742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 156
Study 32204742 — intervention group
Group type: COMPARATOR
Intervention: General Psychiatric Management (GPM)
Number of subjects: 156
Study 32204742 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-predicted optimal treatment
Number of subjects: 156
Study 32204742 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-predicted optimal treatment (top 60% prediction)
Number of subjects: 156
Study 32204742 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-predicted optimal treatment (conservative check)
Number of subjects: 156
Study 34028575 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative telehealth call (3 ± 2 days before surgery)
Number of subjects: 132
Study 34028575 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative telehealth call
Number of subjects: 132
Study 34028575 — intervention group
Group type: COMPARATOR
Intervention: Usual preoperative counseling alone
Number of subjects: 132
Study 34932756 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS Group (continuous stimulation at 100Hz for 100µs with sensory intensity)
Number of subjects: 105
Study 34932756 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst TENS Group (stimulation at 100Hz modulated at 2Hz for 100µs with motor-level intensity)
Number of subjects: 105
Study 34932756 — intervention group
Group type: COMPARATOR
Intervention: Placebo Group (sham electrical stimulation)
Number of subjects: 105
Study 626733905 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoid combined with tiotropium bromide
Number of subjects: 86
Study 626733905 — intervention group
Group type: COMPARATOR
Intervention: Inhaled glucocorticoid
Number of subjects: 86
Study 35298440 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sRAGE
Number of subjects: 277
Study 35298440 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sRAGE in the highest quartile
Number of subjects: 277
Study 33423837 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videos about vaccines and small pharmacy-based financial incentives for vaccine receipt
Number of subjects: 277
Study 32738365 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure therapy in combination with pharmacological treatment (n = 106)
Number of subjects: 212
Study 32738365 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment only (Control group, n = 106)
Number of subjects: 212
Study 36217659 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioral therapy (9 sessions over 8 weeks)
Number of subjects: 86
Study 36217659 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment with medication and vestibular rehabilitation (control group)
Number of subjects: 86
Study 36217659 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioral therapy
Number of subjects: 86
Study 34398958 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric TB therapy
Number of subjects: 850
Study 34398958 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 850
Study 32096209 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of red wine oligomeric procyanidins (OPCs)
Number of subjects: 100
Study 32096209 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 100
Study 35361049 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (fake negative feedback and ostracism)
Number of subjects: 70
Study 35361049 — intervention group
Group type: COMPARATOR
Intervention: No-stress condition
Number of subjects: 70
Study 32992347 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel scoring system based on endoscopic appearance (including tumor size, shape, and mucosal surface)
Number of subjects: 309
Study 32992347 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel scoring system based on endoscopic appearance
Number of subjects: 309
Study 32403902 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 74
Study 32403902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 35220442 — intervention group
Group type: EXPERIMENTAL
Intervention: + UVB WGO
Number of subjects: 46
Study 35220442 — intervention group
Group type: COMPARATOR
Intervention: Control (no WGO)
Number of subjects: 46
Study 35220442 — intervention group
Group type: EXPERIMENTAL
Intervention: – UVB WGO
Number of subjects: 46
Study 32659699 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks web‐based intervention
Number of subjects: 91
Study 32659699 — intervention group
Group type: COMPARATOR
Intervention: Routine face to face occupational therapy intervention (Control)
Number of subjects: 91
Study 36424332 — intervention group
Group type: EXPERIMENTAL
Intervention: Crush mobile application
Number of subjects: 1210
Study 36424332 — intervention group
Group type: COMPARATOR
Intervention: Control group (wellness app)
Number of subjects: 1210
Study 34697783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulmus macrocarpa Hance extract (UME) 500 mg/day for 4 weeks
Number of subjects: 0
Study 34697783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33151988 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigo naturalis (IN) 500 mg, 5 capsules twice a day for 2 weeks
Number of subjects: 46
Study 33151988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 33492301 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg/d for 12 weeks
Number of subjects: 60
Study 32086358 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention in primary healthcare (PHC)
Number of subjects: 200
Study 32086358 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up
Number of subjects: 200
Study 34314941 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous online training with feedback devices (TF)
Number of subjects: 118
Study 34314941 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face training with feedback devices (FF)
Number of subjects: 118
Study 34314941 — intervention group
Group type: COMPARATOR
Intervention: Synchronous online training without feedback devices (TN)
Number of subjects: 118
Study 34314941 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face training without feedback devices (FN)
Number of subjects: 118
Study 33317460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyclonine hydrochloride mucilage (Group N‐AIC)
Number of subjects: 60
Study 33317460 — intervention group
Group type: COMPARATOR
Intervention: Oropharyngeal tetracaine spray (Group S‐AIC)
Number of subjects: 60
Study 34407970 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (N) 240 mg every 2 weeks
Number of subjects: 36
Study 34407970 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab (N + I) 240 mg every 2 weeks + 1 mg/kg every 6 weeks
Number of subjects: 36
Study 33547848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 940
Study 33547848 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 940
Study 32622900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer treatments with statistically significant increase in overall survival
Number of subjects: 234
Study 32622900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer treatments with overall survival as primary outcome
Number of subjects: 234
Study 34519703 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Crural Steal (LCS) and Tongue in Groove (TING) techniques
Number of subjects: 65
Study 34519703 — intervention group
Group type: COMPARATOR
Intervention: Cartilage grafts (Control Group)
Number of subjects: 65
Study 33231029 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface
Number of subjects: 83
Study 33231029 — intervention group
Group type: COMPARATOR
Intervention: Standard PTA treatment
Number of subjects: 83
Study 33231029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study 35260415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tall man lettering (TML) coded labels
Number of subjects: 30
Study 33439282 — intervention group
Group type: COMPARATOR
Intervention: Episiotomy
Number of subjects: 525
Study 33439282 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous perineal tears
Number of subjects: 525
Study 33439282 — intervention group
Group type: COMPARATOR
Intervention: Episiotomy (in vacuum-assisted deliveries)
Number of subjects: 525
Study 35909163 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33 °C (TTM33)
Number of subjects: 1850
Study 32845446 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus individualized feedback via an online dashboard
Number of subjects: 45
Study 32845446 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 45
Study 36424532 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal walking (120 steps/min)
Number of subjects: 78
Study 36424532 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced walking (125 steps/min)
Number of subjects: 78
Study 36424532 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-synchronised walking (120-128 steps/min)
Number of subjects: 78
Study 36424532 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 78
Study 33483110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoventilation therapy (TX, n = 20)
Number of subjects: 37
Study 33483110 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL, n = 17)
Number of subjects: 37
Study 33483110 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC, n = 29)
Number of subjects: 37
Study 32554385 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person NDPP with SMS4PreDM (n=236)
Number of subjects: 488
Study 32554385 — intervention group
Group type: COMPARATOR
Intervention: In-person NDPP alone (n=252)
Number of subjects: 488
Study 36155241 — intervention group
Group type: EXPERIMENTAL
Intervention: Biportal endoscopic discectomy
Number of subjects: 64
Study 36155241 — intervention group
Group type: COMPARATOR
Intervention: Microscopic discectomy
Number of subjects: 64
Study 32902676 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day ejaculatory abstinence period
Number of subjects: 120
Study 32902676 — intervention group
Group type: COMPARATOR
Intervention: 3-day ejaculatory abstinence period
Number of subjects: 120
Study 32102056 — intervention group
Group type: EXPERIMENTAL
Intervention: HA‐EUH (Heat Acclimation with Euhydration)
Number of subjects: 8
Study 32102056 — intervention group
Group type: EXPERIMENTAL
Intervention: HA‐DEH (Heat Acclimation with Dehydration)
Number of subjects: 8
Study 35863814 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVI plus low-voltage area (LVA) modification
Number of subjects: 300
Study 35863814 — intervention group
Group type: COMPARATOR
Intervention: CPVI alone
Number of subjects: 300
Study 35863814 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVI plus LVA modification
Number of subjects: 300
Study 34545117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics administered by paramedics
Number of subjects: 114
Study 34545117 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 114
Study 34545117 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedics trained in sepsis screening and blood culture collection
Number of subjects: 114
Study 34545117 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 90 days
Number of subjects: 114
Study 34545117 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment and delivery of intervention
Number of subjects: 114
Study 34545117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 114
Study 36208220 — intervention group
Group type: EXPERIMENTAL
Intervention: B-SWELL intervention
Number of subjects: 48
Study 36208220 — intervention group
Group type: COMPARATOR
Intervention: Wellness (WE) intervention
Number of subjects: 48
Study 34488061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (intravenous 0.4 ?g/kg/h immediately after anesthesia induction and 0.1 ?g/kg/h after extubation, maintained until 24 h)
Number of subjects: 102
Study 34488061 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 102
Study 34488061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 102
Study 32917645 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1,000 IU/day)
Number of subjects: 62
Study 32917645 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1,200 mg/day)
Number of subjects: 62
Study 32917645 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D
Number of subjects: 62
Study 32917645 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1,000 IU/day) in patients with DBP2 isoform
Number of subjects: 62
Study 32917645 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1,200 mg/day) in patients with DBP2 isoform
Number of subjects: 62
Study 32917645 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D in patients with DBP2 isoform
Number of subjects: 62
Study 32917645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 36219325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandebereho intervention
Number of subjects: 0
Study 36219325 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34129236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichlorphenamide (DCP) 50 mg twice daily
Number of subjects: 63
Study 34129236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 32434574 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized cardiometabolic disease risk score communicated through an online risk score (ORS)
Number of subjects: 7547
Study 32434574 — intervention group
Group type: COMPARATOR
Intervention: Control group who answered questions about CMD risk without receiving an individualized CMD risk score
Number of subjects: 7547
Study 32434574 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized CMD risk score
Number of subjects: 7547
Study 32434574 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history for diabetes type 2
Number of subjects: 7547
Study 32434574 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history for cardiovascular disease
Number of subjects: 7547
Study 32434574 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥25
Number of subjects: 7547
Study 32434574 — intervention group
Group type: EXPERIMENTAL
Intervention: High waist circumference
Number of subjects: 7547
Study 32434574 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 7547
Study 32996796 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 60
Study 32996796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33065228 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 57
Study 33065228 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training with resistive equipment (CTRE)
Number of subjects: 57
Study 33065228 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training with multiple sets (CTMS)
Number of subjects: 57
Study 34583271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warning labels (PWLs)
Number of subjects: 0
Study 34583271 — intervention group
Group type: COMPARATOR
Intervention: Text-only label (control)
Number of subjects: 0
Study 33556123 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-variable gradient boosting model
Number of subjects: 20985
Study 33556123 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeNET score calculated by bedside nurse
Number of subjects: 20985
Study 36288585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375%
Number of subjects: 60
Study 36288585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375% and dexmedetomidine 1 mcg/kg
Number of subjects: 60
Study 36288585 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (N/S) 0.9%
Number of subjects: 60
Study 32400704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparse spectrum with uniform wave vectors (SU) technique
Number of subjects: 0
Study 32400704 — intervention group
Group type: COMPARATOR
Intervention: Sparse spectrum (SS) technique
Number of subjects: 0
Study 32400704 — intervention group
Group type: COMPARATOR
Intervention: Subharmonics complemented discrete Fourier transform (DFT) technique
Number of subjects: 0
Study 32400704 — intervention group
Group type: COMPARATOR
Intervention: Randomized DFT technique
Number of subjects: 0
Study 35620382 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire-assisted reduction technology combined with upright posture (experimental group)
Number of subjects: 99
Study 35620382 — intervention group
Group type: COMPARATOR
Intervention: Guidewire-assisted reduction technology (control group)
Number of subjects: 99
Study 34797324 — intervention group
Group type: EXPERIMENTAL
Intervention: N-butylphthalide (NBP) therapy
Number of subjects: 0
Study 34797324 — intervention group
Group type: COMPARATOR
Intervention: N-butylphthalide placebo
Number of subjects: 0
Study 32571397 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based bloc endocrown
Number of subjects: 156
Study 32571397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic endocrown
Number of subjects: 156
Study 35621342 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrating intimate partner violence advocates
Number of subjects: 0
Study 35621342 — intervention group
Group type: COMPARATOR
Intervention: Enhancing medical training
Number of subjects: 0
Study 32066898 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment
Number of subjects: 1190
Study 32066898 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment visits
Number of subjects: 1190
Study 32066898 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection visits
Number of subjects: 1190
Study 34239102 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry-based metabolomics approaches
Number of subjects: 0
Study 34239102 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for sample preparation, replication and randomization, quantification, recovery and recombination, ion suppression and peak misidentification
Number of subjects: 0
Study 32429465 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (CT + B)
Number of subjects: 141
Study 32429465 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone
Number of subjects: 141
Study 32267481 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 144
Study 32267481 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 144
Study 35615931 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib cessation
Number of subjects: 199
Study 32517393 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-bupivacaine (DB) group (n = 40) - 30 mL bupivacaine 0.25% plus 1 mu g/kg dexmedetomidine
Number of subjects: 80
Study 32517393 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (B) group (n = 40) - 30 mL bupivacaine 0.25% only
Number of subjects: 80
Study 33211886 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (3 g/day)
Number of subjects: 200
Study 33211886 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate mixture (7 g/day)
Number of subjects: 200
Study 34231231 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow, deep breathing (SDB) with inspiratory threshold load
Number of subjects: 0
Study 34231231 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow, deep breathing (SDB) without inspiratory threshold load
Number of subjects: 0
Study 34231231 — intervention group
Group type: COMPARATOR
Intervention: Controlled breathing (CB) at a normal frequency (0.23 Hz)
Number of subjects: 0
Study 36249246 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly SMS intervention for improving feeding practices
Number of subjects: 202
Study 33919722 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mL extra-virgin olive oil supplement
Number of subjects: 3
Study 33919722 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 3
Study 36088325 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (Opalescence Boost 40%)
Number of subjects: 80
Study 36088325 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamide peroxide (Opalescence PF 16%)
Number of subjects: 80
Study 36088325 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 80